Trial Profile
An efficacy trial of docetaxel, cisplatin, and 5-fluorouracil plus cetuximab as an induction regimen in patients with unresectable squamous cell carcinoma of the head and neck.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 27 Jun 2016 New trial record